The biochemical definition of subclinical hypothyroidism (SH) is an elevation of serum Thyroid stimulating hormone (TSH) or thyrotropin level with the associated triioditroponin (T3) and thyroxine (T4) levels in normal reference range. If not prevented at the initial phase, SH eventually progresses into overt hypothyroidism thereby taking a massive toll on the human health. With the advancement of alternative science over the recent decades, a novel pain-free approach has been discussed that successfully treats SH within a span of two months. In this case study, a 23-year old woman reports severe fatigue, mild mood swings and constipation. Physical examination denotes no enlargement of the thyroid gland. However, laboratory results report an elevated serum TSH of 9.85 μIU/mL (reference range: 0.39-6.16 μIU/mL) with normal free T3 (1.79 ng/ml, reference range: 0.52-1.85 ng/ml) and T4(10.17 μIU/mL, reference range: 4.6-11.2 μIU/mL) levels. To prevent the progression of the condition, “Neurotherapy” treatment is provided to the patient. The study sought to determine whether this unique treatment was effective for a patient with SH. Post therapy, laboratory results show a significant reduction of the serum TSH with no associated side-effects, thereby confirming the effectiveness of neurotherapy treatment for the prevention and further progression of this condition.